Medeon Biodesign Asset Resilience Ratio
Medeon Biodesign asset resilience ratio. Medeon Biodesign (6499) has an Asset Resilience Ratio of 32.68% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Medeon Biodesign defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Medeon Biodesign (2017–2025)
Asset resilience ratio of Medeon Biodesign from 2017 to 2025. This chart shows how Medeon Biodesign's Asset Resilience Ratio has changed over time. Read Medeon Biodesign (6499) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Medeon Biodesign's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Medeon Biodesign.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$507.03 Million | 32.68% |
| Total Liquid Assets | NT$507.03 Million | 32.68% |
Asset Resilience Insights
- Very High Liquidity: Medeon Biodesign maintains exceptional liquid asset reserves at 32.68% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Medeon Biodesign Industry Peers by Asset Resilience Ratio
Compare Medeon Biodesign's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
SARTORIUS (UNSP.ADS)/1/5
F:SRT0 |
Medical Instruments & Supplies | 0.26% |
|
Andon Health Co Ltd
SHE:002432 |
Medical Instruments & Supplies | 18.11% |
|
iRay Technology Co Ltd
SHG:688301 |
Medical Instruments & Supplies | 0.68% |
|
Guangzhou Improve Med Instrument
SHE:300030 |
Medical Instruments & Supplies | 4.20% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 7.53% |
|
Nanosonics Ltd
AU:NAN |
Medical Instruments & Supplies | 46.84% |
|
SDI Ltd
AU:SDI |
Medical Instruments & Supplies | 3.36% |
|
Austco Healthcare Ltd
AU:AHC |
Medical Instruments & Supplies | 15.90% |
Medeon Biodesign Asset Resilience Ratio by Year (2017–2025)
Medeon Biodesign asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for Medeon Biodesign.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 39.28% | NT$699.07 Million ≈ $22.02 Million |
NT$1.78 Billion ≈ $56.07 Million |
+2.33pp |
| 2024-12-31 | 36.95% | NT$693.84 Million ≈ $21.86 Million |
NT$1.88 Billion ≈ $59.16 Million |
+4.04pp |
| 2023-12-31 | 32.91% | NT$904.03 Million ≈ $28.48 Million |
NT$2.75 Billion ≈ $86.55 Million |
+6.59pp |
| 2022-12-31 | 26.32% | NT$1.06 Billion ≈ $33.50 Million |
NT$4.04 Billion ≈ $127.28 Million |
-10.67pp |
| 2021-12-31 | 36.99% | NT$1.61 Billion ≈ $50.87 Million |
NT$4.36 Billion ≈ $137.51 Million |
+5.07pp |
| 2020-12-31 | 31.92% | NT$1.06 Billion ≈ $33.34 Million |
NT$3.31 Billion ≈ $104.42 Million |
-20.85pp |
| 2019-12-31 | 52.77% | NT$1.33 Billion ≈ $41.85 Million |
NT$2.52 Billion ≈ $79.30 Million |
-1.65pp |
| 2018-12-31 | 54.42% | NT$1.06 Billion ≈ $33.39 Million |
NT$1.95 Billion ≈ $61.35 Million |
+5.56pp |
| 2017-12-31 | 48.86% | NT$800.44 Million ≈ $25.22 Million |
NT$1.64 Billion ≈ $51.61 Million |
-- |
About Medeon Biodesign
Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular g… Read more